On May 12, 2016 Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, reported that data from four abstracts from the Company’s clinical development program in support of tazemetostat for use in non-Hodgkin lymphoma (NHL) will be presented during the American Society of Hematology (ASH) (Free ASH Whitepaper) Meeting on Lymphoma Biology, to be held in Colorado Springs, CO, from June 18 to June 21, 2016 (Press release, Epizyme, MAY 12, 2016, View Source [SID:1234512293]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Tazemetostat is a first-in-class EZH2 inhibitor currently in phase 2 studies in advanced B-cell non-Hodgkin lymphoma (NHL) and certain genetically defined solid tumors. Among the data to be presented is the first interim report from the Company’s ongoing phase 2 study in patients with NHL.
Planned Presentations:
Oral Presentation: EZH2 as a target for non-Hodgkin lymphoma and beyond: tazemetostat experience; from bench to bedside and back to the bench
Speaker: Vincent Ribrag, MD, Institut Gustave-Roussy, Paris, France
Session Title: Exciting New Mechanisms-Targeted Therapies and Clinical Trials
Date: June 21, 2016
Time: 10:20 a.m. – 10:50 a.m. Mountain Time
Poster: Tazemetostat treatment drives wild-type and mutant EZH2 DLBCL cell lines to a cell fate decision between apoptosis or differentiation (Poster #39)
Author: Michael Thomenius, Ph.D., Epizyme
Date: June 19, 2016
Time: 3:45 p.m. – 5:15 p.m. Mountain Time
Poster: Initial report from a phase 2 multi-center study of tazemetostat (EPZ-6438), an inhibitor of enhancer of zeste-homolog 2 (EZH2), in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (Poster #98)
Author: Franck Morschhauser, MD, PhD, Centre Hospitalier Régional Universitaire de Lille, Lille, France
Date: June 20, 2016
Time: 3:45 p.m. – 5:15 p.m. Mountain Time
Poster: Chromatin flow cytometry based assessment of H3K27me3 pharmacodynamics in blood from diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) patients following exposure to the EZH2 inhibitor tazemetostat reveals disparate response profiles in specific PMBC subpopulations (Poster #38)
Author: Christopher Plescia, Epizyme
Date: June 20, 2016
Time: 3:45 p.m. – 5:15 p.m. Mountain Time
About the Tazemetostat Clinical Trial Program
Tazemetostat, a first-in-class EZH2 inhibitor, is currently being studied in ongoing phase 2 programs in both non-Hodgkin lymphoma and certain genetically defined solid tumors, including INI1-negative and SMARCA4-negative tumors and synovial sarcoma.
The Company has announced plans to initiate additional clinical evaluations of tazemetostat in 2016, including both a combination study with R-CHOP and a combination study with an immune checkpoint inhibitor in patients with NHL, as well as a monotherapy study in patients with mesothelioma.